Prevalence of Hepatitis B in Vallés Occidental. Observational Multicentric Study

Hepatitis B Clinical Trial

Official title:

Prevalence of Hepatitis B in Vallés Occidental. Observational Multicentric Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02548325
• Other study ID #: CorporacionPT
• Status: Completed
• Start date: June 1, 2014
• Est. completion date: July 2017

Study information

• Verified date: January 2019
• Source: Corporacion Parc Tauli
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to evaluate the prevalence of hepatitis B in Vallés Occidental. Also, describe the stage of the disease, and whether if they are under medical treatment or not.

Description:

The hepatitis B virus ( HBV ) is a global health problem . It is estimated that in the world there are about 350-400 million carriers of HBV surface antigen ( HBsAg ) 1 .

The prevalence in Spain is estimated at a 2-7 % and is considered a second intermediate prevalence.

For over 20 years, has carried out a program of primary prevention through universal vaccination against hepatitis B including it in the childhood vaccination schedule and has already been observed that in some estudi3 the prevalence has declined . For this reason , we want to evaluate what is the currently prevalence in our area of influence. There aren't recent studies to assess what is the current status of these patients ( how many , what risk factors which needs of treatment and with answer ...)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1001
• Est. completion date: July 2017
• Est. primary completion date: May 31, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Patients with HBsAg + visited in Digestive/Hepatology outpatient visits and Hepatology of the participating hospitals

Exclusion Criteria:

• Patients < 18 aged

• Duplicity on record

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis B

Intervention

Other:
• Not apply
None. Just registration epidemiology dates

Locations

Country	Name	City	State
Spain	Mútua de Terrassa	Terrassa	Barcelona

Sponsors (3)

Lead Sponsor	Collaborator
Corporacion Parc Tauli	Consorci Sanitari de Terrassa, Hospital Mutua de Terrassa

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	prevalence hepatitis B		12 months
Secondary	stage of the disease and if they are in treatment or not		1 day